C Difficile Infection

IDSA and SHEA released 3 new evidence-based recommendations for treating CDI.

Only 5 patients treated with antibiotic prophylaxis developed bacteremia.

Nearly half of all never C difficile cases are found in nursing home communities.

The overall 90-day cumulative incidences of a first CDI episode was 1.9%.

Strain typing data is not often available to assess whether recurrence is due to CDI relapse or reinfection.

The plan, developed in 2016, has resulted in reductions of most oral antibiotic uses, for both in-hospital and out-of-hospital settings.

A team of investigators stress the impact of the disease on patients as mortality rates grow worldwide.

There was no significant difference in performance between the model with only bile acids compared to models with bile acids and clinical variables.

Hematopoietic stem cell transplant is generally associated with increased C difficile infection risk.

Patients included in the study had a median of 3 prior CDI episodes and 4 risk factors for recurrent infections.

Seres expects to move forward with plans for SER-109 as a novel treatment for CDI.

Multiple studies have found a decrease in CDI rates during the COVID-19 pandemic in comparison to previous years.

Specialist intervention is likely not necessary for low-risk patients; and so, non-liver specialists can be reassured of G/P’s safety profile.

The treatment would represent the first microbiota-based live biotherapeutic to show efficacy in the first recurrence of CDI.

C difficile and sepsis infections can be especially difficult to treat.

SER-109 resulted in a 73% reduction in relative risk for CDI over 8 weeks.

Hospitalizations were more likely in patients with CDI of small bowel and Crohn's disease, with worse outcomes noted in patients admitted to ICU.

There is a substantial health care cost for CDI patients with sepsis.

In data presented at DDW, researchers find a decrease in hospital-acquired CDI infections in 2020 when compared to 2018 and 2019.

The researchers developed a computerized clinical decision support tool to help clinicians prescribe probiotics.

Vonoprazan has shown more potent acid inhibitory effects than PPI.

Females and older patients had higher rates of hospitalizations with CDI than males and younger patients.

COVID-19 patients receiving at least 2 antibiotics were at a higher CDI risk.

Patients with C. diff infections had nearly a 5 day longer length of hospital stay than a group without CDI.

Individuals with malnutrition had higher mortality rates, as well as higher rates of sepsis and pneumonia.